合富 代理 MRI-GUIDED RADIATION系統 (VIEWRAY)

合富 去年EPS挑戰5元【經濟日報╱記者黃文奇／台北報導】 2014.02.20 04:08 am 醫療控股公司F-合富（4745）昨（19）日宣布，獨家代理美國醫療器材公司ViewRay的「磁振動態顯像引導放射治療」系統，該系統近日在美國發布於聖露易斯市華盛頓大學醫學院Siteman抗癌中心，完成首次病人治療。法人表示，合富去年每股稅後純益（EPS）將衝5元。合富表示，ViewRay系統是全球首創也是目前唯一的「磁振動態顯像引導放療系統」，能在治療癌症病患同時，讓放射線照射和連續磁振造影動態同時顯像，這是該領域產品重大技術突破。合富昨日股價開高走高，盤中直奔漲停，終以114元收盤，創下歷史新高價，法人指出，合富昨日股價創下歷史新天價，緣於該公司17日40億元可轉換公司債訂價，轉換價為100元，溢價率為101.5%，讓該股連續三日急漲，近日站上百元大關之後，又連續兩日創下歷史新高價。【2014/02/20 經濟日報】

VIEWRAY™ ANNOUNCES WORLD'S FIRST PATIENTS TREATED USING MRI-GUIDED RADIATION THERAPY  February 5, 2014   CLEVELAND, Ohio, February 5, 2014—The ViewRay™ system, the world's first and only MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a patented combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. MRI-guided radiation therapy enables clinicians to see a patient's internal anatomy in real-time and keep the radiation beams on target when the tumor moves during treatment. One of the initial treatments being delivered on the ViewRay system is stereotactic body radiation therapy (SBRT) for lung cancer. SBRT is a type of radiation therapy in which a few very high doses of radiation are delivered to small, well-defined tumors to kill cancer cells while minimizing exposure to surrounding healthy organs. "Treating patients is a key milestone for ViewRay, but more importantly, it marks a significant advance in cancer care," said Chris A. Raanes, ViewRay president and CEO. "MRI-guided radiation therapy is no longer a research quest; today it has become real and offers physicians a new and powerful weapon for treating cancer." An international leader in cancer treatment and research, the Siteman Cancer Center has a rich history of adopting and helping to develop new technology with a focus on improving patient care and outcomes."Real-time MR guidance offers a way to treat tumors that move with respiration," said Jeffrey Bradley, M.D., S. Lee Kling Professor of Radiation Oncology at Siteman CancerCenter and Washington University School of Medicine. "Our physicians and physicists report the ability to see tumors move in real-time during the entire treatment. This helps to ensure that tumor targets are hit and healthy tissue is spared."